Kategorien
Aktien

Biocept 2,56 EUR +10,34%  ?

SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.
Börse Berlin
Börse Börse Berlin
Symbol B003
EUR
  • Biocept
    Börse Börse Frankfurt
    Symbol B003
    EUR
  • Biocept
    Börse Börse Berlin
    Symbol B003
    EUR
  • BIOCEPT INC
    Börse Börse Düsseldorf
    Symbol B003
    EUR
  • BIOCEPT INC
    Börse Börse Stuttgart
    Symbol B003
    EUR
  • BIOCEPT INC
    Börse Tradegate System der Deutsche Börse AG (60%)
    Symbol B003
    EUR
  • BIOCEPT INC
    Börse Gettex System der Börse München
    Symbol B003
    EUR
  • BIOCEPT INC
    Börse Börse München
    Symbol B003
    EUR
  • BIOCEPT INC
    Börse Quotrix System der Börse Düsseldorf
    Symbol B003
    EUR
  • ISIN US09072V4023 WKN: A2NB41
    Symbol BIOC
    USD
Symbol B003
Währung EUR
Börse Börse Berlin Zeitzone: Europe/Berlin
Firmenname Biocept, Inc
Marktkapitalisierung 95.652.440
Mitarbeiter 133 (+- 34%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

88 oder 177 Mitarbeiter

EBITDA -22.827.566
PEGRatio -0.04
Buchwert 1.594

Biocept underperformed den DAX um -73 % vom 10.07.2020 bis 09.07.2021

18 News & Informationen zur Biocept Aktie

  • Global $18.3 Bn Circulating Tumor Cells Markets to 2027: Growing Demand for Minimally Invasive Diagnostic Procedures to Propel Investments
    prnewswire.com

    Global $18.3 Bn Circulating Tumor Cells Markets to 2027: Growing Demand for Minimally Invasive Diagnostic Procedures to Propel Investments

    /PRNewswire/ — The

  • Global $18.3 Bn Circulating Tumor Cells Markets To 2027: Growing Demand For Minimally Invasive Diagnostic Procedures To Propel Investments
    thestreet.com

    Global $18.3 Bn Circulating Tumor Cells Markets To 2027: Growing Demand For Minimally Invasive Diagnostic Procedures To Propel Investments

    DUBLIN, Aug. 24, 2021 /PRNewswire/ — The

  • Pre-market Movers: GOVX, PROG, SONN, MRIN, NVIV…
    rttnews.com

    Pre-market Movers: GOVX, PROG, SONN, MRIN, NVIV…

    The following are some of the stocks making big moves in Friday's pre-market trading (as of 5.40 A.M. EDT)..

  • Circulating Tumor Cells Market Size Worth $18.3 Billion By 2027: Grand View Research, Inc.
    prnewswire.com

    Circulating Tumor Cells Market Size Worth $18.3 Billion By 2027: Grand View Research, Inc.

    /PRNewswire/ — The global circulating tumor cells market size is expected to reach USD 18.3 billion by 2027, according to a new report by Grand View Research,…

  • Circulating Tumor Cells Market Size Worth $18.3 Billion By 2027: Grand View Research, Inc.
    markets.businessinsider.com

    Circulating Tumor Cells Market Size Worth $18.3 Billion By 2027: Grand View Research, Inc.

    SAN FRANCISCO, Aug. 19, 2021 /PRNewswire/ — The global circulating tumor cells market size is expected to reach USD 18.3 billion by 2027, accordi…

  • The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra...
    news.google.com

    The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc. (NYSE: BIO) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) Gilead Sciences, Inc. (NASDAQ: GILD) GlaxoSmithKline plc (NYSE: GSK) Johnson & Johnson (NYSE: JNJ) Laboratory Corporation of America Holdings (NYSE: LH) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) NanoVibronix, Inc. (NASDAQ: NAOV) (announced intention to enter over-

  • Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2021 Results - Earnings Call Transcript
    seekingalpha.com

    Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2021 Results – Earnings Call Transcript

    Biocept, Inc. (NASDAQ:BIOC) Q2 2021 Earnings Conference Call August 16, 2021 04:30 AM ET Company Participants Bruce Voss – LHA Michael Nall – President & Chief Executive Officer Tim…

  • The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
    markets.businessinsider.com

    The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow

    Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to domin…

  • Biocept Inc Registered Shs hosts conference call for investors
    markets.businessinsider.com

    Biocept Inc Registered Shs hosts conference call for investors

    The company, Biocept Inc Registered Shs, is set to host investors and clients on a conference call on 8/16/2021 3:14:11 PM. The call comes after t…

  • Cancer Biopsy Market Size To Reach $44.51 Billion By 2027 | CAGR: 11.13%: Grand View Research, Inc.
    markets.businessinsider.com

    Cancer Biopsy Market Size To Reach $44.51 Billion By 2027 | CAGR: 11.13%: Grand View Research, Inc.

    SAN FRANCISCO, July 29, 2021/PRNewswire/ — The global cancer biopsy market size is expected to reach USD 44.51 billion by 2027, according to a ne…

  • EDGAR Filing Documents for 0001564590-21-037310
    sec.gov

  • Worldwide Genomic Cancer Panel and Profiling Industry to 2025 - Featuring Anchor, Bioarray Genetics and Burning Rock Among Others
    markets.businessinsider.com

    Worldwide Genomic Cancer Panel and Profiling Industry to 2025 – Featuring Anchor, Bioarray Genetics and Burning Rock Among Others

    DUBLIN, July 5, 2021 /PRNewswire/ — The 'Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Sc…

  • Global Liquid Biopsy Market Size to Reach $6.80 billion by 2028, At CAGR of 20.9%: Allied Market Research
    globenewswire.com

    Global Liquid Biopsy Market Size to Reach $6.80 billion by 2028, At CAGR of 20.9%: Allied Market Research

    Increase in incidences and prevalence of various cancer types, rise in demand for safe and non-invasive procedures, and advantages of liquid biopsy…

  • 10 Penny Stocks to Watch as DogeCoin and Bitcoin Push Up
    pennystocks.com

  • Biocept To Collaborate With Quest Diagnostics To Provide Advanced NGS-Based Liquid Biopsy Testing For Patients With Lung Cancer
    thestreet.com

    Biocept To Collaborate With Quest Diagnostics To Provide Advanced NGS-Based Liquid Biopsy Testing For Patients With Lung Cancer

    Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced a collaboration with Quest Diagnostics

  • Biocept Provides Update On COVID-19 Testing With More Than 350,000 Samples Received To Date
    thestreet.com

    Biocept Provides Update On COVID-19 Testing With More Than 350,000 Samples Received To Date

    Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering

  • Biocept: Record Revenues And Profits Supports Speculative Buy (NASDAQ:BIOC)
    seekingalpha.com

    Biocept: Record Revenues And Profits Supports Speculative Buy (NASDAQ:BIOC)

    Biocept reported record revenues that led to its first profitable quarter. The company continues to process a high volume of COVID-19 tests, which will help fund its neuro-oncology efforts.

  • Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
    markets.businessinsider.com

    Biocept to Present at H.C. Wainwright Virtual BioConnect Conference

    SAN DIEGO, Jan. 4, 2021 /PRNewswire/ — Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and s…

Schreibe einen Kommentar

Wenn du schon einen Account hast, logge dich ein bevor du den Kommentar absendest.

Galue Account Vorteile
  • Battles

    Messe dich mit der Community in Battles.

  • Badges

    Erhalte Belohnungen für Kommentare, die der Community helfen.

  • Mehr Informationen für alle

    Poste Bilder oder Videos zu Themen und Unternehmen und helf dabei, dass Investoren ein kontroverseres Bild erhalten.

  • Kein Datenrisiko

    Du kannst jederzeit deinen Account löschen und gespeicherte Daten einsehen.

Dir gefallen die Informationen zu Biocept?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:

Zur ING Diba

Dir gefallen die Informationen zu Biocept?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:

Zu Trade Republic

Dir gefallen die Informationen zu Biocept?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:

Zur Comdirect

Dir gefallen die Informationen zu Biocept?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:

Zu BUX Zero